dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Spector, Y. | en |
dc.contributor.author | Krikelis, D. | en |
dc.contributor.author | Kotoula, V. | en |
dc.contributor.author | Meiri, E. | en |
dc.contributor.author | Malamou-Mitsi, Vassiliki D. | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Sanden, M. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Benjamin, H. | en |
dc.contributor.author | Aharonov, R. | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Spector, Y. | en |
dc.creator | Krikelis, D. | en |
dc.creator | Kotoula, V. | en |
dc.creator | Meiri, E. | en |
dc.creator | Malamou-Mitsi, Vassiliki D. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Sanden, M. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Benjamin, H. | en |
dc.creator | Aharonov, R. | en |
dc.date.accessioned | 2018-06-22T09:54:25Z | |
dc.date.available | 2018-06-22T09:54:25Z | |
dc.date.issued | 2013 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42349 | |
dc.description.abstract | No data exist on biologic differences between Cancer of unknown primary (CUP) and metastatic solid tumors of known primary site. We assigned a primary tissue of origin in 40 favorable CUP patients (A: serous peritoneal carcinomatosis n = 14, B: axillary adenocarcinoma n = 8, C: upper squamous cervical adenopathy n = 18) by means of a 64-microRNA assay. Subsequently, we profiled the expression of 733 microRNAs (miRs) in the CUP cases and compared results with metastases from 20 ovarian carcinomas, 10 breast adenocarcinomas, 20 squamous head neck or lung tumors. In the Peritoneal CUP versus Ovarian (Known Primary Metastases) KPM comparison, a total of 12 miR were significantly differentially expressed: higher than twofold expression difference in CUP was seen only for miR-513a-5p (3.7-fold upregulated) and miR-483-5p (2.5-fold upregulated), while miR-708 exhibited a twofold downregulation. In the Breast CUP versus Breast KPM comparison, only miR-29c that were downregulated in CUP by 2.7-fold satisfied the FDR threshold. miR-30e and miR-27b, downregulated in ovarian CUPs versus KPMs, were also non-significantly downregulated in breast CUP by 2.0- and 1.4-fold respectively. Six miRs, which belong to the 17-92 oncocluster showed a trend of upregulation in Breast CUP versus Breast KPM cases. A CUP signature remains elusive. © 2012 Springer Science+Business Media Dordrecht. | en |
dc.language.iso | eng | en |
dc.source | Clinical and Experimental Metastasis | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast neoplasms | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Ovarian neoplasms | en |
dc.subject | Retrospective studies | en |
dc.subject | Retrospective study | en |
dc.subject | Clinical article | en |
dc.subject | Prognosis | en |
dc.subject | Statistical significance | en |
dc.subject | Lung neoplasms | en |
dc.subject | Neoplastic | en |
dc.subject | Cancer prognosis | en |
dc.subject | Carcinoma | en |
dc.subject | Male | en |
dc.subject | Protein expression | en |
dc.subject | Follow-up studies | en |
dc.subject | Gene expression regulation | en |
dc.subject | Lymphatic metastasis | en |
dc.subject | Unclassified drug | en |
dc.subject | Down regulation | en |
dc.subject | Upregulation | en |
dc.subject | Lung squamous cell carcinoma | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Squamous cell | en |
dc.subject | Biological | en |
dc.subject | Tumor markers | en |
dc.subject | Cancer of unknown primary site | en |
dc.subject | Unknown primary | en |
dc.subject | Comparative study | en |
dc.subject | Microarray analysis | en |
dc.subject | Microrna 125a-5p | en |
dc.subject | Cancer of unknown primary | en |
dc.subject | Head and neck neoplasms | en |
dc.subject | Carcinomatous peritonitis | en |
dc.subject | Head and neck squamous cell carcinoma | en |
dc.subject | Neoplasm grading | en |
dc.subject | Breast adenocarcinoma | en |
dc.subject | Ovary carcinoma | en |
dc.subject | Micrornas | en |
dc.subject | Primary tumor | en |
dc.subject | Peritoneal neoplasms | en |
dc.subject | Gene expression profiling | en |
dc.subject | Gene expression | en |
dc.subject | Cervical lymphadenopathy | en |
dc.subject | Microrna | en |
dc.subject | Microrna 106a | en |
dc.subject | Microrna 143 | en |
dc.subject | Microrna 149 | en |
dc.subject | Microrna 17 | en |
dc.subject | Microrna 18a | en |
dc.subject | Microrna 1972 | en |
dc.subject | Microrna 20a | en |
dc.subject | Microrna 27b | en |
dc.subject | Microrna 29c | en |
dc.subject | Microrna 30e | en |
dc.subject | Microrna 331-3p | en |
dc.subject | Microrna 483-5p | en |
dc.subject | Microrna 513a-5p | en |
dc.subject | Microrna 574-3p | en |
dc.subject | Microrna 708 | en |
dc.subject | Microrna 92a | en |
dc.subject | Microrna 92b | en |
dc.title | Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1007/s10585-012-9548-3 | |
dc.description.volume | 30 | |
dc.description.issue | 4 | |
dc.description.startingpage | 431 | |
dc.description.endingpage | 439 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.contributor.orcid | Kotoula, V. [0000-0002-8657-9732] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 | |
dc.gnosis.orcid | 0000-0002-8657-9732 | |